Author:
Yu Wanguo,Gao Yaxin,Zhao Zaoya,Long Xiufeng,Yi Yi,Ai Shuo
Abstract
Abstract
Background
Non-alcoholic fatty liver disease (NAFLD) has been well defined as a common chronic liver metabolism disorder. Statins as a first-line therapeutic treatment had some side effects. Here, we found that Fumigaclavine C (FC) was collected from endophytic Aspergillus terreus via the root of Rhizophora stylosa (Rhizophoraceae), had potential anti-adipogenic and hepatoprotective effects both in vitro and in vivo without obvious adverse side effects. However, the mechanisms of the prevention and management of FC for hepatic steatosis are incompletely delineated.
Methods
The pharmacodynamic effects of FC were measured in high-fat diet (HFD)-induced obese mice. Liver index and blood biochemical were examined. Histopathological examination in the liver was performed by hematoxylin & eosin or oil red O. The levels of serum TG, TC, LDL-c, HDL-c, FFA, T-bili, ALT, AST, creatinine, and creatine kinase were estimated via diagnostic assay kits. The levels of hepatic lipid metabolism-related genes were detected via qRT-PCR. The expression levels of hepatic de novo lipogenesis were quantitated with Western blot analysis.
Results
FC-treatment markedly reduced hepatic lipid accumulation in HFD-induced obese mice. FC significantly attenuated the hepatic lipid metabolism and ameliorated liver injury without obvious adverse side effects. Moreover, FC also could dose-dependently modulate the expressions of lipid metabolism-related transcription genes. Mechanically, FC notably suppressed sterol response element binding protein-1c mediated de novo lipogenesis via interfering with the RhoA/ROCK signaling pathway by decreasing the levels of geranylgeranyl diphosphate and farnesyl diphosphate.
Conclusions
These findings suggested that FC could improve hepatic steatosis through inhibiting de novo lipogenesis via modulating the RhoA/ROCK signaling pathway.
Funder
Guangxi Scientific Base and Talent Special Project
National Natural Science Foundation of China
Special Fund for Guangxi University of Science and Technology
Innovation Project of Guangxi Graduate Education
Open Fund of Key Laboratory for Processing of Sugar Resources of Guangxi Higher Education Institutes
Publisher
Springer Science and Business Media LLC
Subject
Complementary and alternative medicine
Reference42 articles.
1. Gao Z, Song GY, Ren LP, Ma HJ, Ma BQ, Chen SC. β-catenin mediates the effect of GLP-1 receptor agonist on ameliorating hepatic steatosis induced by high fructose diet. Eur J Histochem. 2020;64:225–33.
2. Tao WW, Wu J, Xie BX, Zhao YY, Shen N, Jiang S, Wang XX, Xu N, Jiang C, Chen S, Gao X, Xue B, Li CJ. Lipid-induced muscle Insulin resistance is mediated by GGPPS via modulation of the RhoA/Rho kinase signaling pathway. J Biol Chem. 2015;33:20086–97.
3. Rahman MS, Kang I, Lee Y, Habib MA, Choi BJ, Kang JS, Park DS, Kim YS. Bifidobacterium longum subsp infantis YB0411. inhibits adipogenesis in 3T3-L1 Pre-adipocytes and reduces high-fat-diet-induced obesity in mice. J Agric Food Chem. 2021;69:6032–42.
4. Tang QL, Jiang S, Jia WJ, Shen D, Qiu YD, Zhao Y, Xue B, Li CJ. Zoledronic acid, an FPPS inhibitor, ameliorates liver steatosis through inhibiting hepatic de novo lipogenesis. Eur J Pharmacol. 2017;814:169–77.
5. Lee MR, Kim JE, Park JW, Kang MJ, Choi HJ, Bae SJ, Choi YW, Kim KM, Hong JT, Hwang DY. Fermented mulberry (Morus alba) leaves suppress high fat diet-induced hepatic steatosis through amelioration of the inflammatory response and autophagy pathway. BMC Complementary Med Ther. 2020;20:283.